Improvement of Coronary Vascular Functions by Endothelium targeted increase in reactive oxygen species
通过内皮靶向增加活性氧来改善冠状血管功能
基本信息
- 批准号:8854113
- 负责人:
- 金额:$ 26.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至 2016-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAnimal ModelAnti-Inflammatory AgentsAnti-inflammatoryAntioxidantsBiologyBlood VesselsBlood capillariesCaliberCardiopulmonaryCardiovascular DiseasesCardiovascular systemCause of DeathCell ProliferationCenters of Research ExcellenceCessation of lifeClinicalClinical TrialsCoronaryCoronary ArteriosclerosisCoronary CirculationCoronary VesselsCysteineDiseaseEndothelial CellsEndotheliumEventFoundationsGenerationsGoalsGrowthHeartHypoxiaIn VitroInfarctionInstructionLigationMediatingModalityMorbidity - disease rateMusMyocardial IschemiaMyocardiumNitric OxideOutcomeOxidantsOxidation-ReductionPathologyPathway interactionsPharmaceutical PreparationsReactive Oxygen SpeciesReportingRoleSRC geneSignal PathwaySignal TransductionSulfhydryl CompoundsTestingTetanus Helper PeptideTetracyclinesTissuesTransgenic MiceVascular Endothelial CellVascular EndotheliumVascular blood supplyVasodilationWithdrawalbaseblood vessel developmentcapillarydensityendothelial dysfunctionimprovedin vivoin vivo Modelinjury and repairinsightmigrationnovelnovel therapeuticspreconditioningresponsetissue culturetranscription factor
项目摘要
PROJECT SUMMARY (See instructions): Ischemic heart disease (IHD) or myocardial ischemia, is a disease characterized by tissue hypoxia due to reduced blood supply to the heart muscle, usually caused by coronary artery disease. IHD is the leading cause of death and morbidity in the USA. Increase in coronary vessel diameter by vasodilatation (acute response), and increase in vessel density (delayed response) are two major defenses of myocardium from ischemic insults. While coronary vasodilatation is primarily dependent on endothelium-generated nitric oxide (NO), the increase in capillary density initially requires proliferation and migration of vascular endothelial cells (ECs). Increased levels of reactive oxygen species (ROS) are often observed in many cardiovascular diseases, including IHD, giving rise to the notion that ROS cause endothelial dysfunction. However, recent major interventional clinical trials using antioxidants (e.g. HOPE, ATBC), have largely produced negative results in reducing primary endpoints of cardiovascular death and morbidity. Reports from our lab demonstrated that reduced ROS levels inhibited signal transduction events that are essential for NO generation in the vascular endothelium and for coronary vasodilatation. Preliminary Results also showed that c-Src responds to changes in endothelial redox levels and promotes downstream Pl3K-Akt signaling, which in turn activates eNOS and inhibits the growth inhibitory transcription factor, FOXOi, in coronary vascular ECs. This application will test a novel HYPOTHESIS that conditional increase in endothelium-specific-ROS will activate c-Src-Pl3K-Akt-eN0S pathway and inhibit FOXO1, and thus, will result in coronary vasodilatation and increased vessel density in a myocardial ischemia model in vivo. Utilizing a newly developed binary transgenic mice that can induce conditional expression of Nox2 and 2-fold increase in ROS in vascular endothelium, we will determine whether EC-ROS activate c-Src-Pl3K-Akt signaling, proliferation and migration of mouse heart ECs in vitro (Aim 1); whether EC-ROS induce Pl3K-Akt-eNOS activation, NO synthesis and coronary vasodilatation (Aim 2); and whether EC-ROS increase vessel density in ischemic myocardium in an LAD ligation model in vivo (Aim 3).
项目摘要(请参阅说明):缺血性心脏病(IHD)或心肌缺血,是一种疾病,其特征是由于冠状动脉疾病引起的血液供应减少而导致组织缺氧引起的缺氧。 IHD是美国死亡和发病率的主要原因。通过血管舒张(急性反应)增加冠状血管直径,血管密度的增加(延迟反应)是缺血性损伤的两种主要防御能力。尽管冠状动脉血管扩张主要取决于内皮产生的一氧化氮(NO),但毛细血管密度的增加最初需要血管内皮细胞(ECS)的增殖和迁移。在包括IHD在内的许多心血管疾病中,经常观察到活性氧(ROS)的水平升高,这会引起ROS引起内皮功能障碍的观念。但是,最近使用抗氧化剂(例如Hope,ATBC)进行的主要介入临床试验在很大程度上产生了负面结果,从而降低了心血管死亡和发病率的主要终点。我们实验室的报告表明,ROS水平降低抑制了信号转导事件,这对于血管内皮和冠状动脉血管舒张中的任何产生至关重要。初步结果还表明,C-SRC对内皮氧化还原水平的变化做出反应,并促进下游PL3K-AKT信号传导,进而激活eNOS并抑制冠状动脉血管EC中的生长抑制转录因子FoxOI。该应用将检验一个新的假设,即内皮特异性ROS的有条件增加将激活C-SRC-PL3K-AKT-EN0S途径并抑制FOXO1,因此,冠状动脉血管静脉化并增加了体内的血管密度,在体内肌肉症模型中。利用新发达的二元转基因小鼠可以诱导NOX2的条件表达,而血管内皮中ROS的有条件表达,我们将确定EC-ROS是否激活C-SRC-PL3K-AKT信号传导,增殖和小鼠心脏EC的迁移是否在体外(AIM 1); EC-ROS是否诱导PL3K-AKT-ENOS激活,无合成和冠状动脉血管扩张(AIM 2); EC-ROS是否会在体内的LAD连接模型中增加缺血性心肌的血管密度(AIM 3)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ruhul Abid其他文献
Ruhul Abid的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ruhul Abid', 18)}}的其他基金
Sub-cellular Targeting of Endothelial ROS in Myocardial Ischemia
心肌缺血中内皮活性氧的亚细胞靶向
- 批准号:
10705336 - 财政年份:2017
- 资助金额:
$ 26.65万 - 项目类别:
Sub-cellular Targeting of Endothelial ROS in Myocardial Ischemia
心肌缺血中内皮活性氧的亚细胞靶向
- 批准号:
9540053 - 财政年份:2017
- 资助金额:
$ 26.65万 - 项目类别:
Short-Term Training Program to Increase Diversity in Health-Related Research
增加健康相关研究多样性的短期培训计划
- 批准号:
10602535 - 财政年份:2007
- 资助金额:
$ 26.65万 - 项目类别:
Short-Term Training Program to Increase Diversity in Health-Related Research
增加健康相关研究多样性的短期培训计划
- 批准号:
10360156 - 财政年份:2007
- 资助金额:
$ 26.65万 - 项目类别:
Short-Term Training Program to Increase Diversity in Health-Related Research
增加健康相关研究多样性的短期培训计划
- 批准号:
10208927 - 财政年份:2007
- 资助金额:
$ 26.65万 - 项目类别:
Improvement of Coronary Vascular Functions by Endothelium targeted increase in reactive oxygen species
通过内皮靶向增加活性氧来改善冠状血管功能
- 批准号:
9298675 - 财政年份:
- 资助金额:
$ 26.65万 - 项目类别:
Improvement of Coronary Vascular Functions by Endotheliumtargeted-targeted.....
通过内皮细胞靶向改善冠状血管功能......
- 批准号:
8465680 - 财政年份:
- 资助金额:
$ 26.65万 - 项目类别:
Improvement of Coronary Vascular Functions by Endothelium targeted increase in reactive oxygen species
通过内皮靶向增加活性氧来改善冠状血管功能
- 批准号:
9085125 - 财政年份:
- 资助金额:
$ 26.65万 - 项目类别:
相似国自然基金
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Establishment of a Bat Resource for Infectious Disease Research
建立用于传染病研究的蝙蝠资源
- 批准号:
10495114 - 财政年份:2023
- 资助金额:
$ 26.65万 - 项目类别:
A Novel Approach to Target Neutrophilic Airway Inflammation and Airway Hyperresponsiveness in Therapy-Resistant (Refractory) Asthma.
一种针对难治性哮喘中性粒细胞性气道炎症和气道高反应性的新方法。
- 批准号:
10659658 - 财政年份:2023
- 资助金额:
$ 26.65万 - 项目类别:
Pre-clinical testing of low intensity ultrasound as novel strategy to prevent paclitaxel-induced hair follicle damage in a humanized mouse model of chemotherapy-induced alopecia
低强度超声的临床前测试作为预防化疗引起的脱发人源化小鼠模型中紫杉醇引起的毛囊损伤的新策略
- 批准号:
10722518 - 财政年份:2023
- 资助金额:
$ 26.65万 - 项目类别:
Genome Editing Therapy for Usher Syndrome Type 3
针对 3 型亚瑟综合症的基因组编辑疗法
- 批准号:
10759804 - 财政年份:2023
- 资助金额:
$ 26.65万 - 项目类别:
Development of antibody drug conjugates as pan-filo antivirals
开发作为泛型抗病毒药物的抗体药物偶联物
- 批准号:
10759731 - 财政年份:2023
- 资助金额:
$ 26.65万 - 项目类别: